Silexion Therapeutics Receives NASDAQ Delisting Notice
Ticker: SLXNW · Form: 8-K · Filed: May 23, 2025 · CIK: 2022416
Sentiment: bearish
Topics: delisting, nasdaq, listing-standards
Related Tickers: SLXN
TL;DR
NASDAQ's coming for Silexion's listing - stock might get booted!
AI Summary
Silexion Therapeutics Corp. announced on May 23, 2025, that it received a notice from NASDAQ on May 22, 2025, indicating a failure to meet a continued listing rule. The company, formerly known as Biomotion Sciences, is based in Ramat Gan, Israel, and operates in the biological products sector.
Why It Matters
This notice from NASDAQ signifies potential delisting, which could severely impact the liquidity and trading of Silexion Therapeutics' stock.
Risk Assessment
Risk Level: high — Receiving a notice of delisting from a major exchange like NASDAQ presents a significant risk to the company's continued operations and stock value.
Key Players & Entities
- Silexion Therapeutics Corp (company) — Registrant
- NASDAQ (company) — Listing Exchange
- May 23, 2025 (date) — Report Date
- May 22, 2025 (date) — Earliest Event Date
- Biomotion Sciences (company) — Former Company Name
FAQ
What specific NASDAQ continued listing rule did Silexion Therapeutics fail to meet?
The filing states that Silexion Therapeutics Corp. received a notice from NASDAQ indicating a failure to satisfy a continued listing rule or standard, but does not specify which rule was violated.
What is the date of the notice from NASDAQ?
The notice from NASDAQ was received on May 22, 2025.
What is Silexion Therapeutics Corp.'s principal executive address?
Silexion Therapeutics Corp.'s principal executive address is 12 Abba Hillel Road, Ramat-Gan, Israel, 5250606.
When did Silexion Therapeutics Corp. change its name from Biomotion Sciences?
The company changed its name from Biomotion Sciences on May 6, 2024.
What is Silexion Therapeutics Corp.'s Standard Industrial Classification (SIC) code?
Silexion Therapeutics Corp.'s SIC code is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 23, 2025 regarding Silexion Therapeutics Corp (SLXNW).